What insurance policy changes affect HCPCS G0416?

There are 8 tracked policy changes affecting HCPCS G0416, including updates from Aetna, Independence Blue Cross, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS G0416?

Payers that have issued tracked updates for HCPCS G0416 include: Aetna, Independence Blue Cross, Blue Cross & Blue Shield of Mississippi.

How do I get notified when HCPCS G0416 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS G0416. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS G0416?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

G0416 — Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method: Insurance Policy Changes

G0416 Insurance Policy Changes

HCPCS G0416 is officially defined as "Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method." HCPCS G0416 is referenced in 8 tracked payer policy changes from Aetna, Independence Blue Cross, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0416 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Prostate Biopsy (CPB 0698, reviewed 2026-03-02)

Aetna·Effective Mar 2, 2026

Aetna updated its prostate biopsy medical necessity criteria (CPB 0698), effective immediately. The policy now specifies which biopsy techniques are covered (transperineal stereotactic saturation, TRUS-guided, and MRI-guided/fusion approaches) based on specific clinical indications, while designating several newer technologies (AI-based mapping, contrast-enhanced ultrasound, liquid biopsy, micro-ultrasound, and spectral analysis) as experimental and non-covered. Billing teams must update claim processing to enforce these new coverage rules and deny claims for non-covered techniques.

G0416 Insurance Policy Changes

Prostate Biopsy (CPB 0698, reviewed 2026-03-02)

MA00.058, Reimbursement of Surgical Pathology Services for Prostate Biopsy

MA00.058, Reimbursement of Surgical Pathology Services for Prostate Biopsy

00.01.73, Reimbursement of Surgical Pathology Services for Prostate Biopsy

00.01.73, Reimbursement of Surgical Pathology Services for Prostate Biopsy

OfficeLink Updates - May 2025 notices and reminders (PDF)

Prostate Biopsy (CPB 0698, reviewed 2026-10-20)

Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer